Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook

Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook

Submitted by admin on March 3, 2022 - 11:36pm
Source: 
Investors Business Daily
News Tags: 
Aurinia Pharmaceuticals
earnings
Lupkynis
Headline: 
Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook
snippet: 

Aurinia Pharmaceuticals (AUPH) topped Wall Street's fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for its lupus treatment, Lupkynis.

Do Not Allow Advertisers to Use My Personal information